Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine in Myotonia
NCT01939561Phase 3Completed
- Start
- Nov 2013
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lamotrigine in myotonic dystrophy type 1 (DM1), myotonia congenita (MC), paramyotonia congenita (PMC), hyperkalemic periodic paralysis (HyperKPP), Potassium-aggravated myotonia (PAM). Started Nov 2013; status: completed.
02
Drugs
lamotrigine
03
Conditions
myotonic dystrophy type 1 (DM1)myotonia congenita (MC)paramyotonia congenita (PMC)hyperkalemic periodic paralysis (HyperKPP)Potassium-aggravated myotonia (PAM)
Beyond the preview
Go deeper on NCT01939561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939561.